Wave Life Sciences (NASDAQ:WVE) said Takeda (NYSE:TAK) has elected not to exercise its option to further develop its Huntington’s disease treatment candidate WVE-003. As a result, Wave (WVE ...

The termination came after Takeda chose not to exercise its option for the ... to independently advance its clinical-stage Huntington’s disease program, WVE-003, and explore other HTT-targeting ...

IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental ...

A physical isn’t only about unearthing new problems. It's an important time to discuss preventive health, too.

With a lame-duck President to be replaced in a couple of months by a wheeler-dealer with few principles and little in the way of human ...

Q3 2024 Earnings Call Transcript October 31, 2024 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.87, expectations were $-0.93. Operator: Good day, everyone, and welcome ...

As the countdown to a new presidency unfolds, here are some expert-approved methods on how to handle anxiety and stress.

Breakthrough polymer-based therapy shows promise in reversing Huntington's disease symptoms by preventing ... in healthy adults than does moderate exercise, and females may be especially ...

“Fluid retention can be due to many causes, from your diet to medical conditions such as kidney disease ... medicine and pulmonary critical care at Huntington Health in California.

Wave in its filing did not detail why Takeda pulled out of its partnership, noting only that the pharma no longer intends to exercise “and therefore ... various neuro programs, including Huntington’s ...